Blog

Ozempic’s New Frontier: The War on Aging For decades, scientists have searched for a drug capable of slowing aging. Emerging research suggests that the answer may lie in GLP-1s, a class of diabetes and weight-loss medications, including popular brands like Ozempic and Wegovy. Recent studies indicate these drugs offer health benefits that extend beyond their…

With Blood and Growth Disorder Bids Panning Out, Novo Nordisk Plots Path to Rare Disease Leadership Novo Nordisk has been a significant player in the field of rare diseases for over 45 years. However, this sector has often taken a back seat to the company’s more mainstream endeavors in treating diabetes and other chronic conditions….

In Patent Clash Over Injectable Keytruda, Merck and Halozyme Dig In for a Fight In a significant development in the pharmaceutical industry, Merck & Co. and Halozyme Therapeutics are embroiled in a fierce patent dispute concerning an under-the-skin version of Merck’s blockbuster cancer drug Keytruda. The legal skirmish underscores the high stakes involved in drug…

Novo Nordisk Launches NovoCare Pharmacy to Combat Cheaper Compounded Versions of Wegovy Novo Nordisk is taking proactive measures to confront the growing threat posed by compounding pharmacies that have been producing cheaper versions of its popular obesity medication, Wegovy (semaglutide). The Danish pharmaceutical giant has introduced NovoCare Pharmacy, which provides direct home shipping of Wegovy…

The Importance of Real-World Evidence in HIV Treatment Witnessing the devastation caused by the HIV epidemic in the 1980s through my father’s dedication to helping those affected by the virus had a profound effect on my life. His unwavering compassion for individuals living with HIV inspired me to follow in his footsteps and pursue a…

Roche Gains FDA Approval for TNKase: A Significant Advancement in Stroke Treatment In a groundbreaking development for stroke treatment, Roche’s subsidiary, Genentech, has received FDA approval for TNKase (tenecteplase), marking it as the second FDA-approved medication for acute ischemic stroke (AIS). This approval expands Roche’s portfolio within the urgent care landscape, where Genentech has maintained…

Trump’s ‘America First’ Investment Policy Raises Uncertainty for US-China Biotech Dealmaking Impact of the ‘America First Investment Policy’ In a significant move that could reshape the landscape of U.S.-China biotech relations, President Donald Trump recently introduced the “America First Investment Policy.” While this policy is still in its formative stages, it poses potential impediments to…

Moderna’s Stock Slides Amid Review of $590 Million Bird-Flu Vaccine Contract Moderna Inc.’s stock experienced a notable drop of 4% on Thursday following reports of a review by health officials of a significant contract awarded to the company by the Biden administration. This $590 million agreement is intended to support the development of a vaccine…

Eli Lilly’s $27 Billion Commitment to U.S. Drug Manufacturing: A Game-Changer for the Pharmaceutical Industry In a striking move that signifies a major shift in U.S. pharmaceutical production, Eli Lilly announced its most ambitious manufacturing investment to date. During a press conference titled “Lilly in America,” held in Washington, D.C., the Indianapolis-based drugmaker revealed plans…

Eli Lilly, Novo Nordisk Lead Revenue Boom in the ‘Always Tricky’ Q4 In the biopharma industry, revenues continued to surge in the fourth quarter of last year, highlighting a thriving market trend as we progress into 2024. As of February 24, of the world’s 22 biopharma companies that reported quarterly revenue exceeding $2 billion, only…